A Close Look at GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH …

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) continues to trend upward in recent weeks heading back towards all-time highs of $1.20 from last year.

GWPH nearly tripled in March after the Company announced positive Phase 3 trial data for its drug Epidiolex, for the treatment of Dravet syndrome. This is big news for GW as the market for Epidiolex could exceed $1 billion. It also shows that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications. GW saw its market valuation more than double from about $900 million to $1.8 billion on the news which has ignited the entire pot stock sector.

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for

... read more at: http://www.microcapdaily.com/a-close-look-at-gw-pharmaceuticals-plc-adr-nasdaqgwph/116067/